Again, a PARP Inhibitor Has Potential in BRCA+ Breast Cancer Again, a PARP Inhibitor Has Potential in BRCA+ Breast Cancer
A second PARP inhibitor shows promise in germline mutation metastatic breast cancer and is generally well tolerated compared with standard chemotherapy.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news